



ELSEVIER

Clinica Chimica Acta 297 (2000) 315–316



www.elsevier.com/locate/clinchim

Author index

Volume 297 (2000)

- Bakoush, O., see Tencer, J. 297, 73
Bassenge, E., see Schwemmer, M. 297, 207
Bodor, T., see Lakatos, J. 297, 225
Boisson, R.C., Eynard, J.C., Crozier, M., Grafmeyer, D.C., French experience of quality assessment of quantitative urinary analysis 297, 285
Boisson, R.C., see Guder, W.G. 297, 275
Bonini, P., see Guder, W.G. 297, 1
Brand, B., see Dati, F. 297, 239
Bükki, J., see Page, M.K. 297, 67

Crozier, M., see Boisson, R.C. 297, 285
Čvorišćec, D., Early diagnosis of endemic nephropathy 297, 85

Dall'Olio, G., Dorizzi, R.M., Diagnosis of diabetes mellitus at the Hospital of Venice in 1863 297, 17
Dati, F., Brand, B., Standardization activities for harmonization of test results 297, 239
Delanghe, J., see Everaert, K. 297, 183
Denikova, N., see Tzontcheva, A. 297, 217
Dionysiou-Asteriou, A., see Vlaskou, D. 297, 103
Dorizzi, R.M., see Dall'Olio, G. 297, 17

Everaert, K., Hoebeke, P., Delanghe, J., A review on urinary proteins in outflow disease of the upper urinary tract 297, 183
Eynard, J.C., see Boisson, R.C. 297, 285

Fink, B., see Schwemmer, M. 297, 207
Finney, H., see Price, C.P. 297, 55
Fogazzi, G., see Guder, W.G. 297, 275
Fogazzi, G.B., see Kouri, T.T. 297, 305
Frischmuth, N., see Regeniter, A. 297, 261
Galimany, R., see Guder, W.G. 297, 275

Gallagher, H., see Newman, D.J. 297, 43
Gant, V.A., see Kouri, T.T. 297, 305
Grafmeyer, D.C., see Boisson, R.C. 297, 285
Guder, W.G., Boisson, R.C., Fogazzi, G., Galimany, R., Kouri, T., Malakhov, V.N., Plebani, M., External quality assessment of urine analysis in Europe. Results of a round table discussion during the Symposium 'From Uroscopy to Molecular Analysis', Seon, Germany, September 18–20, 1999 297, 275
Guder, W.G., Kutter, D., Bonini, P., From uroscopy to molecular analysis – improving diagnostic information from urine analysis 297, 1
Guder, W.G., see Ivandic, M. 297, 251
Guder, W.G., see Kouri, T.T. 297, 305
Guder, W.G., see Vlaskou, D. 297, 103

Hallander, H.O., see Kouri, T.T. 297, 305
Hoebeke, P., see Everaert, K. 297, 183
Hofmann, W., see Ivandic, M. 297, 251
Hofmann, W., see Kouri, T.T. 297, 305
Hofmann, W., see Vlaskou, D. 297, 103
Holdt-Lehmann, B., Lehmann, A., Korten, G., Nagel, H.-R., Nizze, H., Schuff-Werner, P., Diagnostic value of urinary alanine aminopeptidase and *N*-acetyl- β -D-glucosaminidase in comparison to α_2 -microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients 297, 93
Hotta, O., Yusa, N., Kitamura, H., Taguma, Y., Urinary macrophages as activity markers of renal injury 297, 123
Huber, P., see Regeniter, A. 297, 261

Ivandic, M., Hofmann, W., Guder, W.G., The use of knowledge-based systems to improve medical knowledge about urine analysis 297, 251

PII: S0009-8981(00)00303-X

- Jovanoska, L.K., see Korneti, P.G. 297, 145
 Jung, K., see Koenig, F. 297, 191
- Kitamura, H., see Hotta, O. 297, 123
 Köckerbauer, R., see Schwemmer, M. 297, 207
 Koenig, F., Jung, K., Schnorr, D., Loening, S.A., Urinary markers of malignancy 297, 191
 Korneti, B.K., see Korneti, P.G. 297, 145
 Korneti, P.G., Tasic, V.B., Jovanoska, L.K., Korneti, B.K., Difference between orthostatic and march functional proteinuria by application of stress tolerance test and SDS-PAGE 297, 145
 Korten, G., see Holdt-Lehmann, B. 297, 93
 Kouri, T., see Guder, W.G. 297, 275
 Kouri, T.T., Gant, V.A., Fogazzi, G.B., Hofmann, W., Hallander, H.O., Guder, W.G., Towards European urinalysis guidelines. Introduction of a project under European Confederation of Laboratory Medicine 297, 305
 Kutter, D., see Guder, W.G. 297, 1
 Kutter, D., The urine test strip of the future 297, 297
- Lakatos, J., Bodor, T., Zidaries, Z., Nagy, J., Data processing of digital recordings of microscopic examination of urinary sediment 297, 225
 Lehmann, A., see Holdt-Lehmann, B. 297, 93
 Lehmann, R., Schleicher, E.D., Molecular mechanism of diabetic nephropathy 297, 135
 Loening, S.A., see Koenig, F. 297, 191
 Lupp, P., see Page, M.K. 297, 67
- Malakhov, V.N., see Guder, W.G. 297, 275
- Nagel, H.-R., see Holdt-Lehmann, B. 297, 93
 Nagy, J., see Lakatos, J. 297, 225
 Neumeier, D., see Page, M.K. 297, 67
 Newman, D.J., Thakkar, H., Gallagher, H., Progressive renal disease: does the quality of the proteinuria matter or only the quantity? 297, 43
 Nizze, H., see Holdt-Lehmann, B. 297, 93
- Ots, M., Pechter, Ü., Tamm, A., Characteristics of progressive renal disease 297, 29
 Overton, J., see Twyman, S.J. 297, 155
- Page, M.K., Bükki, J., Lupp, P., Neumeier, D., Clinical value of cystatin C determination 297, 67
 Pechter, Ü., see Ots, M. 297, 29
 Plebani, M., see Guder, W.G. 297, 275
 Price, C.P., Finney, H., Developments in the assessment of glomerular filtration rate 297, 55
 Price, R.G., Urinalysis to exclude and monitor nephrotoxicity 297, 173
- Regeniter, A., Siede, W.H., Scholer, A., Huber, P., Frischmuth, N., Steiger, J.U., Interpreting complex urinary patterns with MDI LABLINK: a statistical evaluation 297, 261
 Rowe, D.J., see Twyman, S.J. 297, 155
- Schleicher, E.D., see Lehmann, R. 297, 135
 Schnorr, D., see Koenig, F. 297, 191
 Scholer, A., see Regeniter, A. 297, 261
 Schuff-Werner, P., see Holdt-Lehmann, B. 297, 93
 Schwemmer, M., Fink, B., Köckerbauer, R., Basenge, E., How urine analysis reflects oxidative stress — nitrotyrosine as a potential marker 297, 207
 Siede, W.H., see Regeniter, A. 297, 261
 Siskos, P.A., see Vlaskou, D. 297, 103
 Steiger, J.U., see Regeniter, A. 297, 261
- Taguma, Y., see Hotta, O. 297, 123
 Tamm, A., see Ots, M. 297, 29
 Tasic, V.B., see Korneti, P.G. 297, 145
 Tencer, J., Bakoush, O., Torffvit, O., Diagnostic and prognostic significance of proteinuria selectivity index in glomerular diseases 297, 73
 Thakkar, H., see Newman, D.J. 297, 43
 Torffvit, O., see Tencer, J. 297, 73
 Twyman, S.J., Overton, J., Rowe, D.J., Measurement of urinary retinol binding protein by immunonephelometry 297, 155
 Tzontcheva, A., Denikova, N., Analytical interference of drugs on the fluorimetric determination of urinary catecholamines 297, 217
- Umbreit, A., Wiedemann, G., Determination of urinary protein fractions. A comparison with different electrophoretic methods and quantitatively determined protein concentrations 297, 163
- Vlaskou, D., Hofmann, W., Guder, W.G., Siskos, P.A., Dionysiou-Asteriou, A., Human neutral brush border endopeptidase EC 3.4.24.11 in urine, its isolation, characterisation and activity in renal diseases 297, 103
 Voswinckel, P., From uroscopy to urinalysis 297, 5
- Wiedemann, G., see Umbreit, A. 297, 163
- Yusa, N., see Hotta, O. 297, 123
- Zidaries, Z., see Lakatos, J. 297, 225



ELSEVIER

Clinica Chimica Acta 297 (2000) 317–321



www.elsevier.com/locate/clinchim

Subject index

Volume 297 (2000)

***N*-Acetyl- β -D-glucosaminidase**; Urinary enzymes; Alanine aminopeptidase; Tubular dysfunction; Glomerulonephritis; α_1 -microglobulin 297, 93

Alanine aminopeptidase; Enkephalinase; Kidney metalloproteinases; Renal diseases (acute toxic tubulointerstitial nephropathy); Urinary enzymes; Urinary proteins 297, 103

Alanine aminopeptidase; Urinary enzymes; *N*-Acetyl- β -D-glucosaminidase; Tubular dysfunction; Glomerulonephritis; α_1 -microglobulin 297, 93

Albuminuria; Hydronephrosis; Reflux; Proteinuria; α_1 -Microglobulin 297, 183

Analytical quality specifications; Urinalysis; Test strips; Microscopy; Bacterial culture; Standardization 297, 305

Ancient and modern concepts of science; Uroscopy; Birth of clinical chemistry; Social implications of scientific progress; History of doctor/patient relationship 297, 5

Aspirin; Epinephrine; Norepinephrine; Interference; Tetracycline; Paracetamol 297, 217

Bacterial culture; Urinalysis; Test strips; Microscopy; Analytical quality specifications; Standardization 297, 305

Battery of tests; Biomarkers; Nephrotoxicity; Sequence of kidney damage; Early markers; Urine analysis 297, 173

Biomarkers; Nephrotoxicity; Sequence of kidney damage; Early markers; Urine analysis; Battery of tests 297, 173

Birth of clinical chemistry; Uroscopy; Ancient and modern concepts of science; Social implications of scientific progress; History of doctor/patient relationship 297, 5

Bladder neoplasm; Tumor marker; Transitional cell carcinoma; Urine; Diagnosis; Prognosis 297, 191

Clearance; Glomerular filtration rate; Endogenous marker; Low molecular weight proteins; Cystatin C 297, 55

Creatinine adjustment; Expert system; Urinary protein pattern analysis; Incidence of tubular proteinuria; Retinol-binding protein; Glomerular selectivity 297, 261

Creatinine clearance; Cystatin C; Metastatic disease; GFR; Renal transplant; Specific 297, 67

Cystatin C; Glomerular filtration rate; Endogenous marker; Clearance; Low molecular weight proteins 297, 55

Cystatin C; Metastatic disease; GFR; Creatinine clearance; Renal transplant; Specific 297, 67

Cytokines; Diabetic nephropathy; Tubular marker proteins; Matrix proteins; Molecular mechanism 297, 135

- Decision support;** Urine protein; Evaluation; Knowledge-based system; Expert system 297, 251
- Diabetes mellitus;** History; Glucose; Venice; Giovanni Bizio; Giacinto Namias 297, 17
- Diabetic nephropathy;** Tubular marker proteins; Matrix proteins; Cytokines; Molecular mechanism 297, 135
- Diagnosis;** Bladder neoplasm; Tumor marker; Transitional cell carcinoma; Urine; Prognosis 297, 191
- Digitised microscope images;** Urinary sediment; Renal diagnosis 297, 225
- Disease activity;** Urinary macrophage; Protein-loading tubulopathy; Lipid-laden macrophages 297, 123
- Early markers;** Biomarkers; Nephrotoxicity; Sequence of kidney damage; Urine analysis; Battery of tests 297, 173
- Electrophoresis;** Proteinuria; Single protein determination 297, 163
- Endemic nephropathy;** Tubulointerstitial lesion; Excretion pattern of α_1 -microglobulin and albumin 297, 85
- Endogenous marker;** Glomerular filtration rate; Clearance; Low molecular weight proteins; Cystatin C 297, 55
- Enkephalinase;** Kidney metalloproteinases; Renal diseases (acute toxic tubulointerstitial nephropathy); Alanine aminopeptidase; Urinary enzymes; Urinary proteins 297, 103
- Epinephrine;** Norepinephrine; Interference; Tetracycline; Aspirin; Paracetamol 297, 217
- Evaluation;** Urine protein; Knowledge-based system; Expert system; Decision support 297, 251
- Excretion pattern of α_1 -microglobulin and albumin;** Endemic nephropathy; Tubulointerstitial lesion 297, 85
- Expert system;** Urinary protein pattern analysis; Creatinine adjustment; Incidence of tubular proteinuria; Retinol-binding protein; Glomerular selectivity 297, 261
- Expert system;** Urine protein; Evaluation; Knowledge-based system; Decision support 297, 251
- External quality assessment;** Inter-laboratory performance; Quality control; Urinary analysis 297, 285
- Functional proteinuria;** Orthostatism; Stress tolerance test, SDS-PAGE 297, 145
- GFR;** Cystatin C; Metastatic disease; Creatinine clearance; Renal transplant; Specific 297, 67
- Giacinto Namias;** History; Diabetes mellitus; Glucose; Venice; Giovanni Bizio 297, 17
- Giovanni Bizio;** History; Diabetes mellitus; Glucose; Venice; Giacinto Namias 297, 17
- Glomerular disease;** α_2 -Macroglobulin; IgG; IgM; Proteinuria; Proteinuria selectivity index 297, 73
- Glomerular filtration rate;** Endogenous marker; Clearance; Low molecular weight proteins; Cystatin C 297, 55
- Glomerular selectivity;** Expert system; Urinary protein pattern analysis; Creatinine adjustment; Incidence of tubular proteinuria; Retinol-binding protein 297, 261
- Glomerulonephritis;** Urinary enzymes; Alanine aminopeptidase; *N*-Acetyl- β -D-glucosaminidase; Tubular dysfunction; α_1 -microglobulin 297, 93
- Glucose;** History; Diabetes mellitus; Venice; Giovanni Bizio; Giacinto Namias 297, 17
- Harmonization;** Quality management; Standardization; Urinalysis; Urinary proteins; Reference material 297, 239
- History;** Diabetes mellitus; Glucose; Venice; Giovanni Bizio; Giacinto Namias 297, 17
- History of doctor/patient relationship;** Uroscopy; Birth of clinical chemistry; Ancient and modern concepts of science; Social implications of scientific progress 297, 5
- Hydronephrosis;** Reflux; Proteinuria; Albuminuria; α -1-Microglobulin 297, 183

- IgG; α_2 -Macroglobulin; Glomerular disease; IgM; Proteinuria; Proteinuria selectivity index** 297, 73
- IgM; α_1 -Macroglobulin; Glomerular disease; IgG; Proteinuria; Proteinuria selectivity index** 297, 73
- Immunonephelometry; Retinol binding protein** 297, 155
- Incidence of tubular proteinuria; Expert system; Urinary protein pattern analysis; Creatinine adjustment; Retinol-binding protein; Glomerular selectivity** 297, 261
- Inter-laboratory performance; External quality assessment; Quality control; Urinary analysis** 297, 285
- Interference; Epinephrine; Norepinephrine; Tetracycline; Aspirin; Paracetamol** 297, 217
- Interlaboratory surveys; Urine analysis; Quality assessments** 297, 275
- Interstitial fibrosis; Proteinuria; Renal disease; Protein type** 297, 43
- Kidney; Tubulointerstitium; Proteinuria; Progression of renal disease; Renin-angiotensin system inhibition; Renoprotection** 297, 29
- Kidney metalloproteinases; Enkephalinase; Renal diseases (acute toxic tubulointerstitial nephropathy); Alanine aminopeptidase; Urinary enzymes; Urinary proteins** 297, 103
- Knowledge-based system; Urine protein; Evaluation; Expert system; Decision support** 297, 251
- Lipid-laden macrophages; Urinary macrophage; Disease activity; Protein-loading tubulopathy** 297, 123
- Low molecular weight proteins; Glomerular filtration rate; Endogenous marker; Clearance; Cystatin C** 297, 55
- α_2 -Macroglobulin; Glomerular disease; IgG; IgM; Proteinuria; Proteinuria selectivity index** 297, 73
- Matrix proteins; Diabetic nephropathy; Tubular marker proteins; Cytokines; Molecular mechanism** 297, 135
- Metastatic disease; Cystatin C; GFR; Creatinine clearance; Renal transplant; Specific** 297, 67
- α -1-Microglobulin; Hydronephrosis; Reflux; Proteinuria; Albuminuria** 297, 183
- α_1 -Microglobulin; Urinary enzymes; Alanine aminopeptidase; *N*-Acetyl- β -D-glucosaminidase; Tubular dysfunction; Glomerulonephritis** 297, 93
- Microscopy; Urinalysis; Test strips; Bacterial culture; Analytical quality specifications; Standardization** 297, 305
- Molecular mechanism; Diabetic nephropathy; Tubular marker proteins; Matrix proteins; Cytokines** 297, 135
- Nephrotoxicity; Biomarkers; Sequence of kidney damage; Early markers; Urine analysis; Battery of tests** 297, 173
- Nitration; Reactive oxygen species; Reactive nitrogen species; Superoxide dismutase** 297, 207
- Norepinephrine; Epinephrine; Interference; Tetracycline; Aspirin; Paracetamol** 297, 217
- Orthostatism; Functional proteinuria; Stress tolerance test, SDS-PAGE** 297, 145
- Paracetamol; Epinephrine; Norepinephrine; Interference; Tetracycline; Aspirin** 297, 217
- Prognosis; Bladder neoplasm; Tumor marker; Transitional cell carcinoma; Urine; Diagnosis** 297, 191
- Progression of renal disease; Kidney; Tubulointerstitium; Proteinuria; Renin-angiotensin system inhibition; Renoprotection** 297, 29
- Protein type; Proteinuria; Renal disease; Interstitial fibrosis** 297, 43
- Protein-loading tubulopathy; Urinary macrophage; Disease activity; Lipid-laden macrophages** 297, 123
- Proteinuria; Electrophoresis; Single protein determination** 297, 163
- Proteinuria; Hydronephrosis; Reflux; Albuminuria; α -1-Microglobulin** 297, 183

- Proteinuria**; Kidney; Tubulointerstitium; Progression of renal disease; Renin-angiotensin system inhibition; Renoprotection 297, 29
- Proteinuria**; Renal disease; Interstitial fibrosis; Protein type 297, 43
- Proteinuria**; α_2 -Macroglobulin; Glomerular disease; IgG; IgM; Proteinuria selectivity index 297, 73
- Proteinuria selectivity index**; α_2 -Macroglobulin; Glomerular disease; IgG; IgM; Proteinuria 297, 73
- Quality assessments**; Urine analysis; Interlaboratory surveys 297, 275
- Quality control**; External quality assessment; Inter-laboratory performance; Urinary analysis 297, 285
- Quality management**; Standardization; Harmonization; Urinalysis; Urinary proteins; Reference material 297, 239
- Reactive nitrogen species**; Reactive oxygen species; Superoxide dismutase; Nitration 297, 207
- Reactive oxygen species**; Reactive nitrogen species; Superoxide dismutase; Nitration 297, 207
- Reference material**; Quality management; Standardization; Harmonization; Urinalysis; Urinary proteins 297, 239
- Reflux**; Hydronephrosis; Proteinuria; Albuminuria; α -1-Microglobulin 297, 183
- Renal diagnosis**; Urinary sediment; Digitised microscope images 297, 225
- Renal disease**; Proteinuria; Interstitial fibrosis; Protein type 297, 43
- Renal diseases (acute toxic tubulointerstitial nephropathy)**; Enkephalinase; Kidney metalloproteinases; Alanine aminopeptidase; Urinary enzymes; Urinary proteins 297, 103
- Renal transplant**; Cystatin C; Metastatic disease; GFR; Creatinine clearance; Specific 297, 67
- Renin-angiotensin system inhibition**; Kidney; Tubulointerstitium; Proteinuria; Progression of renal disease; Renoprotection 297, 29
- Renoprotection**; Kidney; Tubulointerstitium; Proteinuria; Progression of renal disease; Renin-angiotensin system inhibition 297, 29
- Retinol binding protein**; Immunonephelometry 297, 155
- Retinol-binding protein**; Expert system; Urinary protein pattern analysis; Creatinine adjustment; Incidence of tubular proteinuria; Glomerular selectivity 297, 261
- Sequence of kidney damage**; Biomarkers; Nephrotoxicity; Early markers; Urine analysis; Battery of tests 297, 173
- Single protein determination**; Electrophoresis; Proteinuria 297, 163
- Social implications of scientific progress**; Uroscopy; Birth of clinical chemistry; Ancient and modern concepts of science; History of doctor/patient relationship 297, 5
- Specific**; Cystatin C; Metastatic disease; GFR; Creatinine clearance; Renal transplant 297, 67
- Standardization**; Quality management; Harmonization; Urinalysis; Urinary proteins; Reference material 297, 239
- Standardization**; Urinalysis; Test strips; Microscopy; Bacterial culture; Analytical quality specifications 297, 305
- Stress tolerance test, SDS-PAGE**; Orthostatism; Functional proteinuria 297, 145
- Superoxide dismutase**; Reactive oxygen species; Reactive nitrogen species; Nitration 297, 207
- Test parameters**; Urinalysis; Test strip 297, 297
- Test strip**; Urinalysis; Test parameters 297, 297
- Test strips**; Urinalysis; Microscopy; Bacterial culture; Analytical quality specifications; Standardization 297, 305
- Tetracycline**; Epinephrine; Norepinephrine; Interference; Aspirin; Paracetamol 297, 217
- Transitional cell carcinoma**; Bladder neoplasms;

- Tumor marker; Urine; Diagnosis; Prognosis 297, 191
- Tubular dysfunction;** Urinary enzymes; Alanine aminopeptidase; *N*-Acetyl- β -D-glucosaminidase; Glomerulonephritis; α_1 -microglobulin 297, 93
- Tubular marker proteins;** Diabetic nephropathy; Matrix proteins; Cytokines; Molecular mechanism 297, 135
- Tubulointerstitial lesion;** Endemic nephropathy; Excretion pattern of α_1 -microglobulin and albumin 297, 85
- Tubulointerstitium;** Kidney; Proteinuria; Progression of renal disease; Renin-angiotensin system inhibition; Renoprotection 297, 29
- Tumor marker;** Bladder neoplasm; Transitional cell carcinoma; Urine; Diagnosis; Prognosis 297, 191
- Urinalysis;** Quality management; Standardization; Harmonization; Urinary proteins; Reference material 297, 239
- Urinalysis;** Test strip; Test parameters 297, 297
- Urinalysis;** Test strips; Microscopy; Bacterial culture; Analytical quality specifications; Standardization 297, 305
- Urinary analysis;** External quality assessment; Inter-laboratory performance; Quality control 297, 285
- Urinary enzymes;** Alanine aminopeptidase; *N*-Acetyl- β -D-glucosaminidase; Tubular dysfunction; Glomerulonephritis; α_1 -microglobulin 297, 93
- Urinary enzymes;** Enkephalinase; Kidney metalloproteinases; Renal diseases (acute toxic tubulointerstitial nephropathy); Alanine aminopeptidase; Urinary proteins 297, 103
- Urinary macrophage;** Disease activity; Protein-loading tubulopathy; Lipid-laden macrophages 297, 123
- Urinary protein pattern analysis;** Expert system; Creatinine adjustment; Incidence of tubular proteinuria; Retinol-binding protein; Glomerular selectivity 297, 261
- Urinary proteins;** Enkephalinase; Kidney metalloproteinases; Renal diseases (acute toxic tubulointerstitial nephropathy); Alanine aminopeptidase; Urinary enzymes 297, 103
- Urinary proteins;** Quality management; Standardization; Harmonization; Urinalysis; Reference material 297, 239
- Urinary sediment;** Digitised microscope images; Renal diagnosis 297, 225
- Urine;** Bladder neoplasm; Tumor marker; Transitional cell carcinoma; Diagnosis; Prognosis 297, 191
- Urine analysis;** Biomarkers; Nephrotoxicity; Sequence of kidney damage; Early markers; Battery of tests 297, 173
- Urine analysis;** Interlaboratory surveys; Quality assessments 297, 275
- Urine protein;** Evaluation; Knowledge-based system; Expert system; Decision support 297, 251
- Uroscopy;** Birth of clinical chemistry; Ancient and modern concepts of science; Social implications of scientific progress; History of doctor/patient relationship 297, 5
- Venice;** History; Diabetes mellitus; Glucose; Giovanni Bizio; Giacinto Namias 297, 17

the 1990s, the number of people in the world who are under 15 years of age is expected to increase by 1.5 billion (United Nations 1994).

There is a growing awareness of the need to address the needs of children in the 1990s. The United Nations Children's Fund (UNICEF) has been instrumental in this regard, and has been successful in drawing attention to the needs of children in the 1990s. UNICEF has been successful in drawing attention to the needs of children in the 1990s, and has been successful in drawing attention to the needs of children in the 1990s.

There is a growing awareness of the need to address the needs of children in the 1990s. The United Nations Children's Fund (UNICEF) has been instrumental in this regard, and has been successful in drawing attention to the needs of children in the 1990s. UNICEF has been successful in drawing attention to the needs of children in the 1990s, and has been successful in drawing attention to the needs of children in the 1990s.

There is a growing awareness of the need to address the needs of children in the 1990s. The United Nations Children's Fund (UNICEF) has been instrumental in this regard, and has been successful in drawing attention to the needs of children in the 1990s. UNICEF has been successful in drawing attention to the needs of children in the 1990s, and has been successful in drawing attention to the needs of children in the 1990s.

There is a growing awareness of the need to address the needs of children in the 1990s. The United Nations Children's Fund (UNICEF) has been instrumental in this regard, and has been successful in drawing attention to the needs of children in the 1990s. UNICEF has been successful in drawing attention to the needs of children in the 1990s, and has been successful in drawing attention to the needs of children in the 1990s.

There is a growing awareness of the need to address the needs of children in the 1990s. The United Nations Children's Fund (UNICEF) has been instrumental in this regard, and has been successful in drawing attention to the needs of children in the 1990s. UNICEF has been successful in drawing attention to the needs of children in the 1990s, and has been successful in drawing attention to the needs of children in the 1990s.

There is a growing awareness of the need to address the needs of children in the 1990s. The United Nations Children's Fund (UNICEF) has been instrumental in this regard, and has been successful in drawing attention to the needs of children in the 1990s. UNICEF has been successful in drawing attention to the needs of children in the 1990s, and has been successful in drawing attention to the needs of children in the 1990s.

